The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma

Haematologica. 2006 May;91(5):687-90.

Abstract

Immunohistochemically detected over-expression of P53-related protein (P53+++) and absence of P21(waf1) expression (P21-) correspond to loss of function of the P53-gene in diffuse large B-cell lymphoma (DLBCL) patients. Using immunohistochemistry we examined 80 patients with DLBCL and found that 23% had the P53+++/P21- phenotype while 51% had a germinal center (GC) pattern. Both the P53+++/P21- phenotype and the non-GC pattern were associated with inferior outcome. Notably, the prognostic power of the P53+++/P21- phenotype was restricted to patients with a GC pattern, without effect on outcome of patients with a non-GC phenotype. Our results show that immunohistochemistry can parallel gene expression profiling in addressing clinical variability of DLBCL patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bleomycin / administration & dosage
  • Cell Cycle / genetics
  • Cohort Studies
  • Cyclin-Dependent Kinase Inhibitor p21 / analysis
  • Cyclin-Dependent Kinase Inhibitor p21 / deficiency*
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Epirubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Genes, p53
  • Germinal Center / pathology
  • Humans
  • Immunohistochemistry
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • Male
  • Middle Aged
  • Neoplasm Proteins / analysis*
  • Neoplasm Proteins / deficiency
  • Neoplasm Proteins / genetics
  • Phenotype
  • Prednisone / administration & dosage
  • Prognosis
  • Radiotherapy, Adjuvant
  • Reproducibility of Results
  • Rituximab
  • Survival Analysis
  • Survival Rate
  • Tumor Suppressor Protein p53 / analysis*
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Neoplasm Proteins
  • Tumor Suppressor Protein p53
  • Bleomycin
  • Epirubicin
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CEOP protocol 1
  • CHOP protocol
  • VACOP-B protocol